The inspection, which took place between September 23 and September 27, 2024, concluded with 4 observations from the ...

Despite Biocon's assurances that the findings would not impact its business, investor sentiment appeared cautious.

Bangalore: Biocon has announced that the U.S Food and Drug Administration (US FDA) has concluded a surveillance inspection ...

Punjab National Bank: The state-run bank raised ₹ 5,000 crore via Qualified Institutions Placement (QIP). It allotted 48.19 ...

Biocon shares fell 2% to Rs 361.5 after the USFDA issued four observations following an inspection of its Bengaluru API facility. The company will address these within the stipulated time and does not ...

Biocon has entered a partnership with Tabuk for the commercialisation of glucagon-like peptide-1 (GLP-1) products in the ...

Biocon's Bengaluru-based API facility received four observations from the USFDA following an inspection. The company plans to ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, fund raising and ...

Under the terms of this agreement, Biocon will develop and manufacture the products, and Tabuk Pharmaceuticals will hold the ...

The US Food and Drug Administration conducted a surveillance inspection of the API facility (Site 2), located at Bengaluru ...

Karnataka: Biocon Biologics has announced that the US Food and Drug Administration (USFDA) has completed a cGMP inspection at ...

Under the agreement, Biocon will produce and develop the products while Tabuk Pharmaceuticals will market, register, import, ...